F2 Filter and Delivery System
DeviceUse of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
NCT Number: NCT06689839
The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)
Interested in participating?
Request Info50 year and older
All sexes
Interventional
Not applicable
St Andrews War Memorial Hospital, Spring Hill, Queensland, Australia
The study is designed to demonstrate that the F2 Cerebral Protection System (CPS) performs in a consistent manner as the control group in terms of safety, and the F2 Cerebral Protection System (CPS) will be superior in performance when compared to the control group in terms of effectiveness in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
General Exclusion Criteria:
Neurological Exclusion Criteria:
Magnetic Resonance Imaging Exclusion Criteria:
Anatomical and CT Exclusion Criteria:
Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device
Time frame: 30 days post procedure
MACCE includes the composite of death, all stroke, acute kidney injury (AKI) stage 3 or 4 within 7 days post-index procedure Valve Academic Research Consortium 3 (VARC-3) and any major vascular complication (VARC-3)
Time frame: 8-72 hours post procedure
Total new lesion volume (TNLV) in the brain assessed by diffusion weighted magnetic resonance images (DW-MRI)
Time frame: 30 days post procedure
Incidence of all stroke events
Time frame: During procedure
Technical success (% of patients with successful device deployment, position and retrieval) and procedure success (% of patients with technical device success and no device-related safety events)
Time frame: 30 days post procedure
Incidences of all-cause mortality, major stroke, minor stroke events
Time frame: 8-72 hours post procedure
Measure presence or absence of new lesions in the brain, assessed by diffusion weighted magnetic resonance images (DW-MRI)
Time frame: 8-72 hours post procedure
Measure average lesion size in the brain, assessed by diffusion weighted magnetic resonance images (DW-MRI)
Time frame: 30 days post procedure
Use National Institute of Health Stroke Scale (NIHSS) to measure stroke severity on a scale of 0-41 (low score is better outcome).
Time frame: 30 days post procedure
Use Montreal Cognitive Assessment (MoCA) to measure cognitive impairment on a scale of 0-30 (high score is better outcome).
Time frame: 30 days post procedure
Use Modified Rankin Scale (MRS) to measure neurological disability on scale of 0-6 (Low score is better outcome)
Time frame: During procedure
Measure major vascular complications (as defined by VARC-3) & major bleeding (Type 3, Type 4 as defined by VARC- 3)
Time frame: 30 days post procedure
Measure number of hospital readmissions at 30 days and number of ICU readmissions during hospital stay and 30 days
Time frame: Through 30 days
Measure Index hospitalization LOS
Time frame: Through 30 days
Measure Index hospitalization ICU length of stay
Time frame: 30 days post procedure
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a self-reported questionnaire that measures physical function, symptoms, social function, and quality of life, on a scale from 0 to 100 (higher score is better outcome).
Time frame: 30 days post procedure
The Short Form (SF-12) Questionnaire is a self-reported questionnaire that assess the impact of health on an individual's everyday life, on a scale from 0 to 100 (higher score is better health).
Contact information is provided by the study sponsor or research team.
EnCompass Technologies, Inc.
Industry
A Prospective, Randomized, Multicenter, Single-blind Trial to Assess the Safety and Effectiveness of the Encompass F2 Cerebral Protection System Vs. Standard of Care (Unprotected or Sentinel® Cerebral Protection System) During Transfemoral Transcatheter Aortic Valve Replacement
Acronym: SHIELD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07059728
Aortic Stenosis Treated With TAVI, Aortic Valve Disease
Barcelona, Spain
View Trial DetailsNCT07631988
Aortic Stenosis Treated With TAVI
View Trial DetailsNCT07392359
Aortic Stenosis Treated With TAVI
View Trial DetailsNCT07045233
Aortic Stenosis Treated With TAVI, Brain Diseases
Beijing, China
View Trial Details